Évènements de recherche

Symposium SMARCB1 Hope 2023

Sous la direction d'Olivier Delattre et de Franck Bourdeaut de l'Institut Curie à Paris, le Symposium SMARCB1 Hope 2023 a rassemblé 30 experts de renommée internationale dans le domaine du cancer SMARCB1 : chercheurs en oncologie, cliniciens, biologistes, immunologistes et généticiens d'Amérique du Nord, du Royaume-Uni et d'Europe.

Pendant trois jours dans le sud de la France, à travers des présentations, des sessions de travail, des discussions ouvertes et des moments de convivialité, les experts ont :

  • évalué les progrès - et les échecs - scientifiques depuis la découverte du gène SMARCB1 il y a 25 ans par Olivier Delattre et son équipe à l'Institut Curie à Paris

  • exploré de nouvelles approches prometteuses pour le développement de thérapies efficaces

  • mis en lumière et discuté des obstacles au développement de nouvelles thérapies

  • discuté des priorités futures en matière de recherche qui conduiront au financement privé et public des projets

  • semé des graines pour de futures collaborations.

F.Aguilhon/Reportagephotos.fr

Mai 2023 - Saint-Paul-de-Vence, France

F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
1 - 19

Rencontrez les participants

Programme du Symposium 2023

Introduction
Olivier DelattreHistorical Background and Challenges Ahead
Chromatin Remodeling & Epigenetics – Towards Therapeutic Interventions
Charles RobertsSMARCB1-deficient cancers: mechanisms and vulnerabilities
Matthieu GérardSMARCB1 and BRG1 generate subnucleosomes that expand transcription factor binding and function at enhancers
Irwin DavidsonBRG1 in oncogenesis, the example of melanoma
Nada JabadoPRC1, PRC2, BAF and COMPASS complexes: it takes more than 2 to tango in pediatric high grade brain tumors
From Cell-of-Origin to Transformed Cells
Steve BaylinRoles for abnormal DNA methylation and chromatin remodeling in the origins of human cancer – from cell of origin to transformed cells
Sam BehjatiPhylogenetic approaches to finding the cell of origin of rhabdoid tumors
Jarno DrostPatient-specific epigenetic reprogramming drives malignant rhabdoid tumorigenesis
Franck BourdeautCell-of-origin – what mouse models can teach us
Constellation of SMARCB1/A4-deficient Tumors – Overlaps and Specificities
William Foulkes SMARCA4 – updates on associated phenotypes, plausible treatment targets and available resources
Sophie Postel-VinayEpithelioid sarcoma: exploring tumor heterogeneity
Thomas GrünewaldFunctional and translational genomics of Epithelioid sarcoma
Charles KellerFunctional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology
Martin HasselblattRare SMARCB1-deficient tumors of the CNS: Misfits or potential clues to a better understanding of rhabdoid tumor biology?
Gabriel MaloufRole of SMARCB1 alterations in renal medullary carcinomas
Josh SommerAccelerating rare cancer research — the Chordoma Foundation experience
Models, Stratification & Perspectives in Therapeutic Targetting
Annie Huang ATRTs sub-grouping – sufficient for therapeutic stratification?
Marcel KoolSingle cell transcriptional profiling of ATRTs
Paul HuangThe proteomic landscape of SMARCB1-deficient cancers
Dan WilliamsonSubgroup/location-independent prognostic signatures and their correlates in Malignant Rhabdoid Tumors
Mrinal GounderClinical Trials in SMARCB1 altered cancers – Past and Future Directions
Alex KentsisOvercoming clinical resistance to EZH2 inhibition of rhabdoid tumors using rational epigenetic combination therapy
Susan ChiEZH2 inhibition: the long journey of pediatric drug development
Michael FruehwaldRisk stratification in rhabdoid tumors – the need for novel markers AND therapies
Ulrich SchüllerComparative analysis of matched primary and relapsing atypical teratoid/rhabdoid tumors (AT/RT)
The Tumor Cell in its “Omic” & Microenvironment Contexts
Emmanuel DonnadieuImaging of failure and success of CAR T-cells in human tumors
Daniel de CarvalhoViral mimicry response to EZH2 inhibition in SMARCB1-deficient cancers
Eliane PiaggioImmunotherapy of RT: a translational approach
Josh WaterfallTranscriptional dysregulation as a source of tumor specific antigens
David SourdiveSmart cells : an industrial perspective in adoptive cancer immunotherapy
Breakout Brainstorming Sessions